NATH BIOGENES (INDIA) Financial Statement Analysis
|
||
|
The Revenues of NATH BIOGENES (INDIA) have increased by 9.71% YoY .
The Earnings Per Share (EPS) of NATH BIOGENES (INDIA) has decreased by -2.59 % YoY. |
||
NATH BIOGENES (INDIA) Last 5 Annual Financial Results
[BOM: 537291|NSE : NATHBIOGEN]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹365 Cr | ₹333 Cr | ₹301 Cr | ₹278 Cr | ₹13,770,298 Cr |
| Expenses | ₹315 Cr | ₹283 Cr | ₹252 Cr | ₹241 Cr | ₹11,780,424 Cr |
| Operating Profit (Excl OI) | ₹50 Cr | ₹50 Cr | ₹49 Cr | ₹37 Cr | ₹1,989,874 Cr |
| Other Income | ₹4.55 Cr | ₹0.63 Cr | ₹0.55 Cr | ₹1.85 Cr | ₹58,025 Cr |
| Interest | ₹11 Cr | ₹9.21 Cr | ₹10 Cr | ₹11 Cr | ₹367,298 Cr |
| Depreciation | ₹3.82 Cr | ₹3.26 Cr | ₹3.01 Cr | ₹3.08 Cr | ₹450,988 Cr |
| Profit Before Tax | ₹41 Cr | ₹42 Cr | ₹36 Cr | ₹-63 Cr | ₹1,229,613 Cr |
| Profit After Tax | ₹39 Cr | ₹40 Cr | ₹35 Cr | ₹-67 Cr | ₹1,174,569 Cr |
| Consolidated Net Profit | ₹39 Cr | ₹40 Cr | ₹35 Cr | ₹-67 Cr | ₹1,174,569 Cr |
| Earnings Per Share (Rs) | ₹20.31 | ₹20.85 | ₹18.43 | ₹-35.46 | ₹7.34 |
| PAT Margin (%) | 10.58 | 11.91 | 11.62 | -24.21 | 8.53 |
| ROE(%) | 6.15 | 6.70 | 6.28 | -22.48 | 22.76 |
| ROCE(%) | 6.89 | 7.26 | 7.09 | -14.84 | 23.88 |
| Total Debt/Equity(x) | 0.19 | 0.18 | 0.18 | 0.17 | 0.33 |
Key Financials |
||
| Market Cap | : | ₹ 279.9 Cr |
| Revenue (TTM) | : | ₹ 489.8 Cr |
| Net Profit(TTM) | : | ₹ 36.6 Cr |
| EPS (TTM) | : | ₹ 19.3 |
| P/E (TTM) | : | 7.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATH BIOGENES (INDIA) | 0.9% | -4.4% | -8.5% |
| KAVERI SEED COMPANY | 1.2% | -7.9% | -40.5% |
| VENKYS (INDIA) | 0.2% | 11.2% | 10% |
| AVT NATURAL PRODUCTS | 14.7% | 12% | 19.8% |
| BOMBAY SUPER HYBRID SEEDS | -1.2% | -5.4% | NA |
| MANGALAM GLOBAL ENTERPRISE | -0.7% | 4.8% | -1% |
| INDO US BIOTECH | -3.5% | -10.3% | -46.5% |
| JK AGRI GENETICS | 4.9% | 0.1% | -43.3% |
| MANGALAM SEEDS | 3.7% | 1.4% | -17.6% |
NATH BIOGENES (INDIA) Revenues
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | 9.71 % |
| 5 Yr CAGR | -92.83 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹365 Cr | 9.71 | |
| Mar2025 | ₹333 Cr | 10.37 | |
| Mar2024 | ₹301 Cr | 8.26 | |
| Mar2023 | ₹278 Cr | -100.00 | |
| Mar2022 | ₹13,770,298 Cr | - | |
NATH BIOGENES (INDIA) Operating Profit
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | 0.20 % |
| 5 Yr CAGR | -92.92 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹50 Cr | 0.20 | |
| Mar2025 | ₹50 Cr | 1.99 | |
| Mar2024 | ₹49 Cr | 31.59 | |
| Mar2023 | ₹37 Cr | -100.00 | |
| Mar2022 | ₹1,989,874 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -8.66 % |
| 5 Yr CAGR | -1.29 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 13.72% | -8.66 | |
| Mar2025 | 15.02% | -7.57 | |
| Mar2024 | 16.25% | 21.54 | |
| Mar2023 | 13.37% | -7.47 | |
| Mar2022 | 14.45% | - | |
NATH BIOGENES (INDIA) Profit After Tax
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | -2.57 % |
| 5 Yr CAGR | -92.43 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹39 Cr | -2.57 | |
| Mar2025 | ₹40 Cr | 13.11 | |
| Mar2024 | ₹35 Cr | Positive | |
| Mar2023 | ₹-67 Cr | Negative | |
| Mar2022 | ₹1,174,569 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -11.17 % |
| 5 Yr CAGR | 5.53 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 10.58 % | -11.17 | |
| Mar2025 | 11.91 % | 2.50 | |
| Mar2024 | 11.62 % | Positive | |
| Mar2023 | -24.21 % | Negative | |
| Mar2022 | 8.53 % | - | |
NATH BIOGENES (INDIA) Earnings Per Share (EPS)
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | -2.59 % |
| 5 Yr CAGR | 28.97 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹20 | -2.59 | |
| Mar2025 | ₹21 | 13.13 | |
| Mar2024 | ₹18 | Positive | |
| Mar2023 | ₹-35 | Negative | |
| Mar2022 | ₹7.34 | - | |
NATH BIOGENES (INDIA) Return on Capital Employed (ROCE)
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | -5.10 % |
| 5 Yr CAGR | -26.71 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 6.89% | -5.10 | |
| Mar2025 | 7.26% | 2.40 | |
| Mar2024 | 7.09% | Positive | |
| Mar2023 | -14.84% | Negative | |
| Mar2022 | 23.88% | - | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Current Share Price | : | ₹147.3 |
| Current MarketCap | : | ₹ 279.9 Cr |
| Updated EOD on | : | Sep 22,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | 0.9% |
-4.4% |
-8.5% |
| SENSEX | 0.7% |
-3.9% |
-8.9% |
NATH BIOGENES (INDIA) related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about NATH BIOGENES (INDIA) Financials
How the annual revenues of NATH BIOGENES (INDIA) have changed ?
The Revenues of NATH BIOGENES (INDIA) have increased by 9.71% YoY .
How the Earnings per Share (EPS) of NATH BIOGENES (INDIA) have changed?
The Earnings Per Share (EPS) of NATH BIOGENES (INDIA) has decreased by -2.59 % YoY .
Check out Intrinsic Value of Peers of NATH BIOGENES (INDIA)
Compare Stock Analytics of Peers of NATH BIOGENES (INDIA)
KAVERI SEED COMPANY LTD vs VENKYS (INDIA) LTD vs AVT NATURAL PRODUCTS LTD
BOMBAY SUPER HYBRID SEEDS LTD vs MANGALAM GLOBAL ENTERPRISE LTD vs
KAVERI SEED COMPANY LTD vs VENKYS (INDIA) LTD vs AVT NATURAL PRODUCTS LTD
BOMBAY SUPER HYBRID SEEDS LTD vs MANGALAM GLOBAL ENTERPRISE LTD vs
